NCT03670251

Brief Summary

In Vietnam, the prevalence of hepatitis C virus (HCV) infection is estimated between 0.4% and 5%, which is much higher than the prevalence in Europe or in the USA. After HCV diagnosis, HCV viral load quantification is crucial in order to distinguish recovered from active (on-going) HCV infection and hence identify those who need antiviral treatment to cure HCV infection. HCV viral load quantification is also important to assess treatment efficacy. Currently, anti-HCV antibodies detection is available around the country. However, access to confirmation of HCV viremia remains scarce particularly in decentralized areas. One of the reason is the limited number of laboratories able to perform this complex biological measurement; moreover, these laboratories are situated only in large urban centres. Blood sampling using DBS could help overcome this difficulty of access to a laboratory, and widen access to HCV viral load monitoring. The present MOVIDA Hep study aims at validating the use of DBS to measure HCV viral load as compared to plasma (gold standard). A secondary objective is to evaluate the measurement of HCV core antigen on DBS. For this, 315 patients need to be enrolled form outpatient clinics in Hanoi. The laboratory in charge of these measurements would be the virology laboratory of the National Institute of Hygiene and Epidemiology (NIHE) in Hanoi (Vietnam).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
315

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 10, 2018

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 13, 2018

Completed
8 months until next milestone

Study Start

First participant enrolled

May 9, 2019

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 11, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 11, 2019

Completed
Last Updated

April 1, 2022

Status Verified

February 1, 2020

Enrollment Period

2 months

First QC Date

September 10, 2018

Last Update Submit

March 21, 2022

Conditions

Keywords

HCV Viral Load, Dried Blood Spot, HCV Core Ag

Outcome Measures

Primary Outcomes (1)

  • Quantification of HCV RNA on DBS compared to plasma as gold standard

    Sensitivity and specificity of HCV RNA VL measured on DBS collected by venipuncture

    Up to 4 weeks

Secondary Outcomes (6)

  • Quantification of HCV RNA measured on DBS using plasma as gold standard

    Up to 4 weeks

  • Correlation between HCV RNA VL measured on DBS and on plasma.

    Up to 6 months

  • Quantification of HCV core antigen using HCV RNA VL as gold standard

    Up to 8 weeks

  • Correlation between HCV core antigen and HCV RNA VL on plasma

    Up to 6 months

  • Quantification of HCV core antigen measured on DBS using HCV RNA VL measured on plasma as gold standard.

    Up to 8 weeks

  • +1 more secondary outcomes

Study Arms (1)

Blood sampling

OTHER

blood samples from venepuncture (10mL) and from fingertip (approximatively 0.4mL) on a dried blood spots

Procedure: Blood sampling

Interventions

Blood sample of 10 mL by venipuncture and 0,4 mL by finger prick

Blood sampling

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ≥18 years of age
  • Known HCV infection
  • Willing to participate to the study by giving his/her consent.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Dong Da Hospital

Hanoi, Vietnam

Location

Nam Tu Liem Hospital

Hanoi, Vietnam

Location

Related Publications (4)

  • Taieb F, Tran Hong T, Ho HT, Nguyen Thanh B, Pham Phuong T, Viet Ta D, Le Thi Hong N, Ba Pham H, Nguyen LTH, Nguyen HT, Nguyen TT, Tuaillon E, Delaporte E, Le Thi H, Tran Thi Bich H, Nguyen TA, Madec Y. First field evaluation of the optimized CE marked Abbott protocol for HIV RNA testing on dried blood spot in a routine clinical setting in Vietnam. PLoS One. 2018 Feb 9;13(2):e0191920. doi: 10.1371/journal.pone.0191920. eCollection 2018.

    PMID: 29425216BACKGROUND
  • Taieb F, Tram TH, Ho HT, Pham VA, Nguyen L, Pham BH, Tong LA, Tuaillon E, Delaporte E, Nguyen AT, Bui DD, Do N, Madec Y. Evaluation of Two Techniques for Viral Load Monitoring Using Dried Blood Spot in Routine Practice in Vietnam (French National Agency for AIDS and Hepatitis Research 12338). Open Forum Infect Dis. 2016 Jul 7;3(3):ofw142. doi: 10.1093/ofid/ofw142. eCollection 2016 Sep.

    PMID: 27704001BACKGROUND
  • Soulier A, Poiteau L, Rosa I, Hezode C, Roudot-Thoraval F, Pawlotsky JM, Chevaliez S. Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring. J Infect Dis. 2016 Apr 1;213(7):1087-95. doi: 10.1093/infdis/jiv423. Epub 2015 Sep 2.

    PMID: 26333945BACKGROUND
  • Tran TH, Nguyen BT, Nguyen TA, Pham TTP, Nguyen TTT, Mai HTB, Pham HB, Nguyen TM, Phan HTT, Do NT, Ait-Ahmed M, Taieb F, Madec Y. Dried blood spots perform well to identify patients with active HCV infection in Vietnam. J Viral Hepat. 2020 May;27(5):514-519. doi: 10.1111/jvh.13263. Epub 2020 Feb 11.

Related Links

MeSH Terms

Conditions

Hepatitis C

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Blood-Borne InfectionsCommunicable DiseasesInfectionsHepatitis, Viral, HumanVirus DiseasesFlaviviridae InfectionsRNA Virus InfectionsHepatitisLiver DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Officials

  • Fabien TAIEB, MD, PhD, MPH

    Institut Pasteur

    PRINCIPAL INVESTIGATOR
  • Tuan Anh NGUYEN, MD, PhD

    National Institute of Hygiene and Epidemiology (NIHE)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2018

First Posted

September 13, 2018

Study Start

May 9, 2019

Primary Completion

July 11, 2019

Study Completion

July 11, 2019

Last Updated

April 1, 2022

Record last verified: 2020-02

Data Sharing

IPD Sharing
Will not share

Locations